Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.37 |
| ▸ | PPARA | Q07869 | 6/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.37 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.35 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30687749 | 1.00 | PPARG (0.37) | PPARGPPARAPPARDPARP1PANK3 | |
| SCHEMBL26681318 | 0.92 | PPARG (0.38) | PPARGPPARAPPARDPARP1PANK3 | |
| SCHEMBL26682347 | 0.90 | SLC6A9 (0.36) | PPARGPPARAPPARDPARP1PANK3 | |
| SCHEMBL30687628 | 0.90 | SLC6A9 (0.36) | PPARGPPARAPPARDPARP1PANK3 | |
| SCHEMBL26682773 | 0.90 | PARP1 (0.38) | PPARGPPARAPPARDPARP1SSTR5 | |
| SCHEMBL26681672 | 0.89 | PPARG (0.40) | PPARGPPARAPPARDPANK3MGLL | |
| SCHEMBL30687575 | 0.89 | PPARG (0.40) | PPARGPPARAPPARDPANK3MGLL | |
| SCHEMBL26681639 | 0.88 | PARP1 (0.36) | PPARGPPARAPARP1PARP2 | |
| SCHEMBL30687772 | 0.88 | PPARG (0.40) | PPARGPPARAPPARDPARP1PARP2 | |
| SCHEMBL26681175 | 0.88 | PPARG (0.40) | PPARGPPARAPPARDPARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | PPARG 3997/4885PPARA 3873/4885PPARD 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.